Selection of human antibody fragments directed against tumor T-cell epitopes for adoptive T-cell therapy

Cytometry Part A

Volumn 73, Issue 11, 2008, Pages 1093-1099

  Willemsen, Ralph ^a   Chames, Patrick ^b   Schooten, Erik ^a   Gratama, Jan Willem ^a   Debets, Reno ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CNRS   (France)

Author keywords

Antibodies; Phage display; T cell therapy

Indexed keywords

EPITOPE; IMMUNOGLOBULIN F(AB) FRAGMENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELANOMA ANTIGEN; PEPTIDE; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOGENE THERAPY; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY ENGINEERING; ANTIBODY SPECIFICITY; CANCER PATIENT; CD4+ T LYMPHOCYTE; CELL ISOLATION; CLONE; CYTOKINE PRODUCTION; GENE CONSTRUCT; GENE THERAPY; GENETIC TRANSDUCTION; GENOME ANALYSIS; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOGLOBULIN GENE; IN VITRO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; PHAGE DISPLAY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THERAPY EFFECT; TREATMENT RESPONSE; TUMOR CELL DESTRUCTION;

ANTIBODIES, NEOPLASM; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL;

EID: 55949123671     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.20644     Document Type: Review

References (50)

1. Brennan DJ, Kelly C, Rexhepaj E, Dervan PA, Duffy MJ, GallagherW M. Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer. Cancer Genomics Proteomics 2007;4:121-134.
2. Sears C, Armstrong SA. Microarrays to identify new therapeutic strategies for cancer. Adv Cancer Res 2007;96:51-74.
3. Gilboa E. The promise of cancer vaccines. Nat Rev Cancer 2004;4:401-411.
4. Marincola FM, Jaffee EM, Hicklin D J, Ferrone S. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273.
5. Rubin B, Malissen B, Jorgensen PN, Zeuthen J. Recognition of insulin on MHC-class-II-expressing L929 cells by antibody and T cells. Res Immunol 1989;140:67-74.
6. Tamminen WL, Wraith D, Barber BH. Searching for MHC-restricted anti-viral antibodies: Antibodies recognizing the nucleoprotein of influenza virus dominate the serological response of C57BL/6 mice to syngeneic influenza-infected cells. Eur J Immunol 1987;17:999-1006.
7. Hoogenboom HR, Chames P. Natural and designer binding sites made by phage display technology. Immunol Today 2000;21:371-378.
8. Garboczi DN, Hung DT, Wiley DC. HLA-A2-peptide complexes: Refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. Proc Natl Acad Sci USA 1992;89:3429-3433.
9. Chames P, Hufton SE, Coulie PG, Uchanska-Ziegler B, Hoogenboom HR. Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library. Proc Natl Acad Sci USA 2000;97:7969-7974.
10. Willemsen RA, Debets R, Hart E, Hoogenboom HR, Bolhuis RLH, Chames P. A phage display selected Fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes. Gene Ther 2001;8:1594-1600.
11. Chames P, Willemsen RA, Rojas G, Dieckmann D, Rem L, Schuler G, Bolhuis RLH, Hoogenboom HR. TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity. J Immunol 2002;169:1110-1118.
12. Willemsen RA, Ronteltap C, Chames P, Debets R, Bolhuis RLH. T cell retargeting with MHC class i-restricted antibodies: The CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production. J Immunol 2005;174:7853-7858.
13. Altman JD, Moss PAH, Goulder PJR, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996;274:94-96.
14. Denkberg G, Cohen CJ, Segal D, Kirkin AF, Reiter Y. Recombinant human singlechain MHC-peptide complexes made from E. coli by in vitro refolding: Functional single-chain MHC-peptide complexes and tetramers with tumor associated antigens. Eur J Immunol 2000;30:3522-3532.
15. Chames P, Hoogenboom HR, Henderikx P. Selection of antibodies against biotinylated antigens. Methods Mol Biol 2002;178:147-157.
16. Chattopadhyay P, Melenhorst J, Ladell K, Gostick E, Scheinberg P, Barrett A, Wooldridge L, Roederer M, Sewell A, Price D. Techniques to improve the direct ex vivo detection of low frequency antigen-specific CD8+ T cells with peptide-major histocompatibility complex class I tetramers. Cytometry Part A 2008;73A:in press. DOI: 10.1002/cyto.a.20642 (this issue).
17. Cecconi V, Moro M, Del Mare S, Dellabona P, Casorati G. Use of MHC class II tetramers to investigate CD4+ T cell responses: problems and solutions. Cytometry Part A 2008;73A:in press. DOI: 10.1002/cyto.a.20603 (this issue).
18. de Haard HJ, van Neer N, Reurs A, Hufton SE, Roovers RC, Henderikx P, de Bruïne AP, Arends JW, Hoogenboom HR. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies J Biol Chem 1999;274:18218-18230.
19. Biddison WE, Turner RV, Gagnon SJ, Lev A, Cohen CJ, Reiter Y. Tax and M1 peptide/ HLA-A2-specific Fabs and T cell receptors recognize nonidentical structural features on peptide/HLA-A2 complexes. J Immunol 2003;171:3064-3074.
20. Cohen CJ, Denkberg G, Lev A, Epel M, Reiter Y. Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: New tools to study antigen presentation and TCR-peptide-MHC interactions. J Mol Recogn 2003;16:324-332.
21. Cohen CJ, Hoffmann N, Farago M, Hoogenboom HR, Eisenbach L, Reiter Y. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Cancer Res 2002;62:5835-5844.
22. Cohen CJ, Sarig O, Yamano Y, Tomaru U, Jacobson S, Reiter Y. Direct phenotypic analysis of human MHC class I antigen presentation: visualization, quantitation, and in situ detection of human viral epitopes using peptide-specific, MHC-restricted human recombinant antibodies. J Immunol 2003;170:4349-4361.
23. Denkberg G, Cohen CJ, Lev A, Chames P, Hoogenboom HR, Reiter Y. Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC-restricted T cell receptor-like specificity. Proc Natl Acad Sci USA 2002;99:9421-9426.
24. Held G, Matsuo M, Epel M, Gnjatic S, Ritter G, Lee SY, Tai TY, Cohen CJ, Old LJ, Pfreundschuh M, Reiter Y, Hoogenboom HR, Renner C. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments. Eur J Immunol 2004;34:2919-2929.
25. Lev A, Denkberg G, Cohen CJ, Tzukerman M, Skorecki KL, Chames P, Hoogenboom HR, Reiter Y. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit. Cancer Res 2002;62:3184-3194.
26. Hulsmeyer M, Chames P, Hillig RC, Stanfield RL, Held G, Coulie PG, Alings C, Wille G, Saenger W, Uchanska-Ziegler B, Hoogenboom HR, Ziegler A. A major histocompatibility complex-peptide-restricted antibody and T cell receptor molecules recognize their target by distinct binding modes: Crystal structure of human leukocyte antigen (HLA)-A1-MAGE-A1 in complex with FAB-HYB3. J Biol Chem 2005;280: 2972-2980.
27. Dieckmann D, Schultz ES, Ring B, Chames P, Held G, Hoogenboom HR, Schuler G. Optimizing the exogenous antigen loading of monocyte-derived dendritic cells. Int Immunol 2005;17:621-635.
28. Zehn D, Cohen CJ, Reiter Y, Walden P. Extended presentation of specific MHC-peptide complexes by mature dendritic cells compared to other types of antigen-presenting cells. Eur J Immunol 2004;34:1551-1560.
29. Zehn D, Cohen CJ, Reiter Y, Walden P. Efficiency of peptide presentation by dendritic cells compared with other cell types: Implications for cross-priming. Int Immunol 2006;18:1647-1654.
30. Yamano Y, Cohen CJ, Takenouchi N, Yao K, Tomaru U, Li HC, Reiter Y, Jacobson S. Increased expression of human T lymphocyte virus type I (HTLV-I) Tax11-19 peptide-human histocompatibility leukocyte antigen A*201 complexes on CD4+ CD25+ T cells detected by peptide-specific, major histocompatibility complex-restricted antibodies in patients with HTLV-I-associated neurologic disease. J Exp Med 2004;199:1367-1377.
31. Denkberg G, Lev A, Eisenbach L, Benhar I, Reiter Y. Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen. J Immunol 2003;171:2197-2207.
32. Lum LG, Davol PA, Lee RJ. The new face of bispecific antibodies: Targeting cancer and much more. Exp Hematol 2006;34:1-6.
33. Behar G, Siberil S, Groulet A, Chames P, Pugniere M, Boix C, Sautes-Fridman C, Teillaud JL, Baty D. Isolation and characterization of anti-Fc(gamma)RIII (CD16) lama single-domain antibodies that activate natural killer cells. Protein Eng Des Sel 2008;21:1-10.
34. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;5594:850-854.
35. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 2002;99:16168-16173.
36. Willemsen RA, Debets R, Chames P, Bolhuis RL. Genetic engineering of T cell specificity for immunotherapy of cancer. Hum Immunol 2003;64:56-68.
37. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 1989;86:10024-10028.
38. Weijtens ME, Willemsen RA, Valerio D, Stam K, Bolhuis RL. Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines and specifically lyse tumor. J Immunol 1996;157:836-843.
39. Pinthus JH, Waks T, Malina V, Kaufman-Francis K, Harmelin A, Aizenberg I, Kanety H, Ramon J, Eshhar Z. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J Clin Invest 2004;114:1774-1781.
40. Stauss HJ, Cesco-Gaspere M, Thomas S, Hart DP, Xue S-A, Holler A, Wright G, Perro M, Little A-M, Pospori C, King J, Morris EC. Monoclonal T-cell receptors: New reagents for cancer therapy. Mol Ther 2007;15:1744-1750.
41. Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol 1999;163:507-513.
42. Willemsen RA, Weijtens MEM, Ronteltap C, Eshhar Z, Gratama JW, Chames P, Bolhuis RLH. Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. Gene Ther 2000;7:1369-1377.
43. Stanislawski T, Voss RH, Lotz C, Sadovnikova E, Willemsen RA, Kuball J, Ruppert T, Bolhuis RL, Melief CJ, Huber C, Stauss HJ, Theobald M. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2001;2:962-970.
44. Xue SA, Gao L, Hart D, Gillmore R, Qasim W, Thrasher A, Apperley J, Engels B, Uckert W, Morris E, Stauss H. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood 2005;106:3062-3067.
45. Kessels HWHG, Wolkers MC, van den Boom MD, van den Valk MA, Schumacher TNM. Immunotherapy through TCR gene transfer. Nat Immunol 2001;2:957-961.
46. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;5796:126-129.
47. Lamers CHJ, Sleijfer S, Vulto AG, Kruit WHJ, Kliffen M, Debets R, Gratama JW, Stoter G. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience. J Clin Oncol 2006;13:20e-22e.
48. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, Chen CC, Yang JC, Rosenberg SA, Hwu P. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006;12:6106-6115.
49. Derby MA, Alexander-Miller MA, Tse R, Berzofsky JA. High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. J Immunol 2001;166:1690-1697.
50. Schaft N, Lankiewicz B, Drexhage J, Berrevoets C, Moss DJ, Levitsky V, Bonneville M, Lee SP, McMichael AJ, Gratama JW, Bolhuis RL, Willemsen R, Debets R. T cell re-targeting to EBV antigens following TCR gene transfer: CD28-containing receptors mediate enhanced antigen-specific IFNgamma production. Int Immunol 2006;18:591-560.